Pfizer-BioNTech seek U.S. OK for second COVID booster for 65 and older

Pfizer Inc and its German partner BioNTech SE an application with U.S. regulators seeking emergency use authorization for a second booster shot of their COVID-19 vaccine for people aged 65 and older. The submission to the U.S. Food and Drug Administration includes data collected in Israel, where a second booster is authorized for many people over age 18. read more An analysis of data from over a million adults 60 years and older showed rates of confirmed infections and severe illness were lower among individuals who received an additional booster dose of the vaccine administered at least four months after an initial booster (third) dose compared to those who received only one booster dose, the companies said.